Allogene Therapeutics, Inc.

NASDAQ:ALLO

Biotechnology

Healthcare
$0.74 +1.02%

+$0.02 today

Market cap
$257.81M
Beta
0.46
P/E (TTM)
-2.7
EPS (TTM)
-$0.72
52W Low $0.98High $4.46

Volume 8.49M

Average 10.19M

Returns on capital

Allogene Therapeutics, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-65.3%

avg -27.1%

ROIC

-52.8%

avg -33.1%

ROA

-45.9%

avg -30.7%

Analysis

ROA is currently the strongest return metric at -45.9% versus its period average of -30.7%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

David D. Chang

Co-Founder & DirectorUSD 1.14M665.15M2.11%

Joshua A. Kazam

Co-Founder & DirectorUSD 1.14M490<0.01%

Zachary J. Roberts

President, CEO & DirectorUSD 750.76K48——

Arie S. Belldegrun

Co-Founder & Executive ChairmanUSD 728.73K77——

Geoffrey Parker

Executive Vice President & Chief Financial OfficerUSD 707K61——

Benjamin Beneski

Senior Vice President & Chief Technical Officer—49——

Earl Douglas

Senior Vice President, General Counsel, Compliance Officer & Corporate Secretary—63——

Annie Yoshiyama

Senior VP of Finance, Corporate Controller & Principal Accounting Officer—42124.52K0.05%

Christine Cassiano

Executive Vice President, Chief Corporate Affairs & Brand Strategy Officer————

Susan R. Lundeen

Chief People Officer—60——

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Jun 18, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

0

$0.00

Sells

14

$667,852.95

Net Transaction Value

−$667,852.95

Net selling

Most Active

Beneski Benjamin Machinas

4 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Oct 21, 26

Parker Geoffrey M.

Direct

Sell$48.7K
Aug 21, 26

Douglas Earl Martin

Direct

Sell$63K
Apr 21, 26

Yoshiyama Annie

Direct

Sell$22.1K
Mar 31, 26

Beneski Benjamin Machinas

Direct

Sell$7.2K
Mar 16, 26

Beneski Benjamin Machinas

Direct

Sell$11.9K
Mar 16, 26

Chang David D

Direct

Sell$118K
Mar 2, 26

Beneski Benjamin Machinas

Direct

Sell$18.5K
Feb 2, 26

Beneski Benjamin Machinas

Direct

Sell$13.1K
Feb 2, 26

Chang David D

Direct

Sell$171.5K
Feb 2, 26

Parker Geoffrey M.

Direct

Sell$42.2K

1–10 of 14

Summary

Insiders reported 0 buys worth $0.00 and 14 sells worth $667,852.95 over the last 12 months. That adds up to net selling of $667,852.95. Beneski Benjamin Machinas was the most active insider with 4 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A4 analysts
RevenueN/AN/AN/A
N/A5 analysts
Net IncomeN/AN/AN/A
N/A5 analysts
EBITN/AN/AN/A
N/A5 analysts

Analysis

Analysis will appear once historical growth or forward estimates are available for this company.

Competitors

Who does Allogene Therapeutics, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about ALLO's management, answered from reported figures.

Who manages ALLO?

Allogene Therapeutics, Inc. (ALLO) lists 10 active executives. The top listed executive is David D. Chang, Co-Founder & Director.

Are ALLO insiders buying or selling?

Recent insider activity shows net buying of $111.60M.